DAFTAR PUSTAKA

1. Guyton., Hall., 2008. Buku Ajar Fisiologi Kedokteran edisi 11. Jakarta:EGC
2. Staf pengajar departemen Farmakologi universitas sriwijaya,. 2009. Kumpulan kuliah
farmakologi. Jakarta: EGC
3. Olsoh Farn, James., 2003. Belajar mudah farmakologi. Jakarta: EGC
4. Goodman,. Gilman. 2008. Dasar farmakologi terapi edisi 10. Jakarta: EGC
5. Syarif amir, dkk., 2005. Farmakologi dan terapi. Jakarta: Balai penerbit FKUI
6. Nader, HB et al. (1999). "Heparan sulfates and heparins: similar compounds
performing the same functions in vertebrates and invertebrates?". Braz. J. Med. Biol.
Res. 32
7. Acang, Nursiwan. Pemakaian dan Pemantauan Obat-Obatan Antitrombosis dalam
Buku Ilmu Penyakit Dalam edisi 5 editor oleh: Sudoyo, A.W., Bambang Setioyohadi,
Idrus Alwi, Marcellus Simadibrata K, Siti Setiati. Pusat Penerbit Ilmu Penyakit
Dalam, Jakarta: 2009
8. Mary J. Mycek et al. Farmakologi Ulasan Bergambar Edisi 2 Widya Medika 2001;
9. Hedi R., Vincent H.S. Gan., Antikoagulan, Antitrombosit, Trombolitik, dan
Hemostatik. Farmakologi dan Terapi Edisi 4 FK UI
10. Dewoto, H.R. Antikoagulan, Antitrombotik, Trombolitik dan Hemostatik dalam Buku
Farmakologi Dan Terapi edisi 5 editor oleh: Gunawan, S.G., Rianto Setiabudy,
Nafrialdi, Elysabeth. Departemen Farmakologi dan Terapeutik FKUI, Jakarta: 2009
11. Aguilar OM, Kleiman NS. Low molecular weight heparins. J Invasive Cardiol 2001
12. Mathis AS, Meswani P, Spinler SA. Risk stratification in non-ST segment elevation
acute coronary syndormes with special focus on recent guidelines. Pharmacotherapy
13. Racine E. Differentiation of the low-molecular-weight heparins. Pharmacotherapy
2001
14. Peterson D, Harward S, Lawson J.H. Anticoagulation strategies for venous
thromboembolism. Perspect Vasc Surg Endovasc Ther 2009
15. Mansjoer A, Triyanti K, Savitri R et al. Trombosis Vena. Dalam : Kapita Selekta
Kedokteran Jilid I. edisi 3. Jakarta : Media Aesculapius Fakultas Kedokteran
Universitas Indonesia;2001.
16. Gunawan GS, Nafrialdi SR, Elysabeth. Farmakologi Dan Terapi. Dewoto HR. anti
koagulan, antitrombotik, trombolitik dan hemostatik. Departemen Farmkologi dan
Terapetik FKUI : Jakarta. 2007;804-819
17. Adiwijawa JA. Efek dan Resistansi Clopidogrel pada Sindrom Koroner Akut. Dalam
medika jurnal kedokteran Indonesia. Edisi No 05 Vol XXXVII - 2011 Available at
http://www.jurnalmedika.com
18. TNKase offi cial FDA informations, side eff ects and uses [Internet]. 2011 [cited 2013
Apr 10]. Available from: www.drugs.com/pro/tnkase.html?printable=1.
19. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute
myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J
2012
20. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the
Management of ST-Elevation Myocardial Infarction: a report of the American
College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol
2013
21. Tran A, PharmD, Ceng-Lai A. Dabigatran Etexilate, the first oral anticoagulant
available in the united states since warfarin. Cardiology in Review. 2011;19:154-61.
22. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med.
2009;361:1139-51.
23. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939)- an oral,
direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J
Clin Pharmacol. 2006;63:469-76.
24. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban
versus warfarin in nonvalvular atrial fibrillation. N Eng J Med. 2011;365:883-91.
25. Raghavan N, Frost CE, Yu Z, He K, Zhang H, humphreys G, et al. Apixaban
metabolism and pharmacokinetics after oral administration to humans. Drug Metab
Dispos. 2009;37:74-81
26. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa
inhibitor apixaban in japanese patients with non-valvular atrial fibrillation. Circ J.
2011;75:1852-9.
27. CDK 187 / vol. 38 no. 6 / Agustus - September 2011
28. Badan POM. informasi produk terapeutik Vol. 22 / No. 1 NOVEMBER 2012